Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:39 AM
Ignite Modification Date:
2025-12-25 @ 3:39 AM
NCT ID:
NCT07002502
Brief Summary:
The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.
Detailed Description:
The "PRaG-1" cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201.
Patients will receive "PRaG-1" treatment twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed at pre-treatment, after 5 days of treatment, and at the end of treatment. A 5 ml blood sample and 2 g of tissue will be collected via biopsy before and after treatment for storage, to be used in subsequent analysis of immune function-related indicators. The clinical trial will be terminated if any of the following occur: disease progression, intolerable toxicity, withdrawal of the informed consent form (ICF), death, or other conditions specified in the protocol that require discontinuation of treatment.
Study:
NCT07002502
Study Brief:
Protocol Section:
NCT07002502